Results 131 – 140 of 151 for vaccine Covid (0.04 seconds)

Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

conducted from 2017 to 2023 continuing through the COVID-19 pandemic. Patients with blood cancer remain at a disproportionately high risk of severe ...

Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial

patients from 2019 to 2021, continuing through the COVID-19 pandemic.7 Patients with blood cancer remain at a disproportionately high risk of severe ...

Fixed-duration Calquence-based regimens recommended for approval in the EU by CHMP for 1st-line chronic lymphocytic leukaemia

patients from 2019 to 2021, continuing through the COVID-19 pandemic.7 Patients with blood cancer remain at a disproportionately high risk of severe ...

AstraZeneca launches global R&D Postdoctoral Challenge to accelerate scientific discovery and diversity

AstraZeneca launches global R&D Postdoctoral Challenge to accelerate scientific discovery and diversity

Egypt

Response during COVID-19 pandemic

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

period, and a pre-specified analysis censoring for COVID-19-related deaths was conducted to assess the impact. PFS was further improved in both arms, ...

Annual report 2022

■ Oncology 26% ■ Cardiovascular, Renal & Metabolism 29% ■ Respiratory & Immunology 16% ■ Vaccine & Immune Therapies 0% ■ Rare Disease 19% ...

Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukaemia, with 77% of patients progression free at three years in AMPLIFY Phase III trial

patients respectively. There were over twice as many COVID related deaths in the Calquence plus venetoclax with obinutuzumab arm compared with the ...

Taiwan

阿斯特捷利康 COVID-19 疫苗相關問題請造訪疫苗網站，網址為 https://www.azcovid-19.com/asia/tw/zh.html

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants

anticipated. Global public health measures to control COVID-19 have reduced the circulation of all respiratory viruses, including RSV. Sufficient ...

Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next